Abstract
The selective 5-hydroxytryptamine3 (5HT3) antagonist ondansetron has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy. This double-blind study compared the efficacy and safety of three doses of intravenous ondansetron in the prevention of nausea and vomiting associated with high-dose (≥100 mg/m2) cisplatin chemotherapy. A total of 125 patients were randomized (1∶1∶1) to receive 0.015, 0.15, or 0.30 mg/kg every 4 h for a total of 3 doses. All patients were monitored for emetic episodes, adverse events, and laboratory safety parameters for 24 h following cisplatin administration. The 0.15-mg/kg dose was superior to the 0.015-mg/kg dose with respect to the median number of emetic episodes (P=0.033) and complete response (no emetic episodes,P=0.005). No statistically significant difference was found between the 0.15 and the 0.30-mg/kg groups. The most common adverse event was headache. Three 0.15-mg/kg doses of intravenous ondansetron are safe, effective, and adequate for the control of cisplatin-induced emesis.
Similar content being viewed by others
References
Fozard IR (1984) Neuronal 5-HT receptors in the periphery. Neuropharmacology 23: 1473
Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Bordin LA, Braun TJ, Young CW (1981) Antiemetic efficacy of high dose metolopramide; randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905
Gralla RJ, Tyson LB, Kris MG, Clark RA (1987) The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 71: 289
Grunberg SM, Stevenson LL, Russell CA, McDermed JE (1989) Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7: 1137
Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G, York M, Siddiqui T, Finn A (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J. Clin Oncol 9:721
Khojasteh A, Sartiano G, Tapazoglou E, Lester E, Gandara D, Bernard S, Finn A (1990) Ondansetron for the prevention of emesis induced by high-dose cisplatin. Cancer 66:1101
Kris MG, Gralla RJ, Clark RA, Tyson LB (1988) Dose-ranging evaluation of the serotonin antagonist GRC507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 6: 659
Kris MG, Gralla RJ, Clark RA, Tyson LB (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. Natl Cancer Inst 81: 42
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816
Von Hoff D, Schilsky R, Reicher CM (1979) Toxic effects ofcis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63: 1527
Author information
Authors and Affiliations
Additional information
This study was supported by a grant from Glaxo Inc.
Rights and permissions
About this article
Cite this article
Grunberg, S.M., Lane, M., Lester, E.P. et al. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother. Pharmacol. 32, 268–272 (1993). https://doi.org/10.1007/BF00686171
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686171